
    
      A Randomized, Double Blind, Placebo-controlled, Multicenter, Parallel Group Study to Assess
      the Efficacy and Safety of Fixed-dose Combination RHB-104 in Subjects with Moderately to
      Severely Active Crohn's Disease.
    
  